Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

The randomised trial met its primary endpoint, demonstrating a significant increase in clinical responders in the therapy arm, with 77% of these subjects achieving an absence of phlebotomy ...

If you’re in the market for a new laptop or tablet you may have come across several options that fall under the Windows on Arm ecosystem. What’s Arm, you ask? Simply put, it’s the processor ...

Arm Holdings is reportedly aiming to make its own data center chip. The move would be a big departure from its traditional licensing business. The big bet could lead to massive upside, or blow up ...

Arm Shocks the Semiconductor Industry by Announcing It May Sell Its Own Chips Your email has been sent Arm could compete with its customers, including Qualcomm. Meta has already inked a deal with ...

British semiconductor giant Arm Holdings plc is planning to manufacture its own chips in 2025, according to the Financial Times and has started competing against its own clients for deals.

The UK-based chip designer pivots to selling its own chips, securing Meta as its first major customer, and challenging long-time industry partners. In a landmark shift, Arm has secured Meta as the ...